Last week at the Cell Therapy Cardiology Conference held at Columbia Presbyterian Hospital we heard KOL's (Key Opinion Leaders) from just about every stem cell company at the meeting. Several presentations held great interest for all, one in particular from Dr Zeiher of t2cure was quite interesting. t2cure (German - private) has been working on bone marrow derived cell therapy product for AMI. According to Dr Zeiher (founder) pre-conditioning cardiac ischemic patients with sound wave energy (much like the probes that are used to break up kidney stones). The company believes that they can pre-condition ischemic hearts, active a homing signal (stromal derived factor-1 SDF-1) that will allow the active cells in marrow (CD34+ / CXCR4+) cells to lock in on the ischemic area and create new blood vessel formation.
Daily Dose Conclusion: Sanuwave (OTCBB: SNWV) has demonstrated that their device does enhance healing and probably through the mechanism that Dr Zeiher was presenting last week. Sanuwave missed their primary endpoint (100% wound closure in diabetic foot ulcers - DFU) but they really only just missed it. Wounds that had not healed without their therapy healed 99%. The last 1% is almost impossible to get perfect closure, and as a result, the FDA has requested they do another trial. While we are not sure what the action plan at Sanuwave will be, we do see this technology as important to the stem cell space.